Adverum Biotechnologies Reports Second Quarter 2022 Financial Results
11 août 2022 16h05 HE
|
Adverum Biotechnologies, Inc.
- Dosing first Phase 2 LUNA trial participant with ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) on track for the third quarter of 2022 and preliminary data anticipated...
Adverum Biotechnologies to Participate in the 2nd Annual H.C. Wainwright Ophthalmology Virtual Conference
10 août 2022 16h05 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01 août 2022 16h05 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Biotechnologies Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After a Single IVT Injection of ADVM-022 (Ixo-vec) in the OPTIC Study in Wet AMD
15 juil. 2022 08h32 HE
|
Adverum Biotechnologies, Inc.
- Study participants had an 81%-98% reduction in annualized anti-VEGF injections and demonstrated continuous aflibercept expression levels through three years - Mean best-corrected visual acuity...
Adverum Biotechnologies Announces Upcoming Data Presentation at ASRS 2022
08 juil. 2022 08h00 HE
|
Adverum Biotechnologies, Inc.
- Adverum to present new best-corrected visual acuity (BCVA) data from the OPTIC Trial of ADVM-022 (ixoberogene soroparvovec) in wet AMD REDWOOD CITY, Calif., July 08, 2022 (GLOBE NEWSWIRE)...
Adverum Biotechnologies Completes IND Amendment and Prepares to Initiate the Phase 2 LUNA Trial of ADVM-022 in Wet AMD
06 juil. 2022 16h05 HE
|
Adverum Biotechnologies, Inc.
- Cash runway extended into 2025 due to corporate restructuring to prioritize the clinical development of ADVM-022 and provide additional resources beyond anticipated one-year topline results of the...
Adverum Biotechnologies Granted Priority Medicines (PRIME) Designation by European Medicines Agency for ADVM-022 in Wet AMD
24 juin 2022 08h00 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., June 24, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Biotechnologies Presents Three-Year Aflibercept Protein Expression and Improvement in Anatomic Outcomes After a Single IVT Injection of ADVM-022 in the OPTIC Study in Wet AMD
09 juin 2022 08h00 HE
|
Adverum Biotechnologies, Inc.
- Three-year aflibercept protein expression demonstrates continuous and consistent therapeutic levels from ADVM-022 in OPTIC study subjects with wet age-related macular degeneration (wet AMD) - New...
Adverum Biotechnologies Announces New Data at the Macula Society’s 2022 Annual Meeting
02 juin 2022 16h05 HE
|
Adverum Biotechnologies, Inc.
- OPTIC study of intravitreal gene therapy with ADVM-022 (AAV.7m8-aflibercept) for wet AMD shows therapeutic levels of aflibercept out to three years- New evaluation of the impact of baseline levels...
Adverum Biotechnologies Presents Research Pipeline Data Supporting Utility of its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene Therapy
19 mai 2022 08h00 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...